Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Total Debt
Short-term and long-term borrowings combined.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 28612.6% from a year ago
Total debt stood at $351.73M at the end of Q1 FY2026, up 28612.6% from a year earlier and up 339.9% from the prior quarter. Over 3 fiscal years it compounded at +274.1% a year.
Context
- Total debt amounted to 47.0% of total assets at the end of Q1 FY2026, up 46.7 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +28612.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 79.96M USD
- Year-over-year change
- +7872.3%
- 3-year CAGR
- +274.1%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 79.96M | +7872.3% |
| FY2024 | 2024-12-31 | 1M | -95.2% |
| FY2023 | 2023-12-31 | 21.11M | +1282.6% |
| FY2022 | 2022-12-31 | 1.53M | — |
Total Debt vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 total debt of $351.73M is the highest of the 8 companies compared; the peer median is $1.11M.
- Its year-over-year change of +28612.6% is the highest of 6, against a peer median of -20.1%.
- Total debt amounts to 47.0% of total assets for ZBIO, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $351.73M | +28612.6% | +274.1% | 47.0% | |
| Mar 2026 | $25.43M | -10.2% | -7.3% | 9.7% | |
| Mar 2026 | $10.99M | -41.5% | -30.0% | 17.3% | |
| Mar 2026 | $1.99M | -20.1% | +45.7% | 1.0% | |
UPBUpstream Bio, Inc. | Mar 2026 | $1.11M | -34.5% | +138.1% | 0.4% |
| Dec 2025 | $456K | +330.2% | +7.7% | 4.0% | |
| Sep 2026 | $0 | — | -61.1% | 0.0% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding ZBIO) | $1.11M | -20.1% | +0.2% | 1.0% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.